← Back to Search

Antiresorptive Agent

Denosumab only for Osteoporosis

Phase 4
Waitlist Available
Led By Benjamin Leder, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months after first dose of study drug
Awards & highlights

Study Summary

This trial looks at the effects of two osteoporosis medications, teriparatide and denosumab, on the bone of postmenopausal women.

Eligible Conditions
  • Osteoporosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months after first dose of study drug
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months after first dose of study drug for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cancellous Bone Formation Rate at Month 3

Trial Design

3Treatment groups
Active Control
Group I: Denosumab onlyActive Control1 Intervention
one dose of subcutaneous injection denosumab
Group II: Denosumab and teriparatideActive Control2 Interventions
daily subcutaneous injection teriparatide for 3 months plus one dose of subcutaneous injection denosumab
Group III: Teriparatide onlyActive Control1 Intervention
daily subcutaneous injection teriparatide for 3 months

Find a Location

Who is running the clinical trial?

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NIH
483 Previous Clinical Trials
1,086,902 Total Patients Enrolled
36 Trials studying Osteoporosis
40,383 Patients Enrolled for Osteoporosis
Massachusetts General HospitalLead Sponsor
2,925 Previous Clinical Trials
13,197,867 Total Patients Enrolled
19 Trials studying Osteoporosis
1,288 Patients Enrolled for Osteoporosis
Benjamin Leder, MD4.25 ReviewsPrincipal Investigator - Massachusetts General Hospital
Massachusetts General Hospital
3 Previous Clinical Trials
142 Total Patients Enrolled
3 Trials studying Osteoporosis
142 Patients Enrolled for Osteoporosis
1Patient Review
I question the medical ethics of this doctor. They conducted a study on human subjects that involved deliberately changing our hormones and giving us thyroxine intravenously until we vomited. This likely caused permanent health conditions.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
Benjamin Leder, MD 2019. "Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04026256.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top